Juno Therapeutics Inc. ("Juno") is an American biopharmaceuticals company developing multiple cell-based product candidates to treat B-cell malignancies, solid tumors and myeloma.

According to a law firm's press release, the Complaint alleges Juno materially misled investors by failing to disclose the May 2016 death of a patient in the Company’s Phase 2 trial of product candidate JCAR015. These omissions caused Juno to trade at artificially inflated prices, and certain insiders participated in the heavy selling of shares in the weeks prior to the disclosure of the death. Then, following the death of two other patients in June and July, the U.S. Food and Drug Administration issued a clinical hold on the study, and Juno disclosed the patients’ deaths.

On this news, Juno's share price fell significantly in value, dropping almost 32%, or $13.01 per share, to close at $27.81 per share on July 8, 2016.

Then on Wednesday, July 13, 2016, after the close of trading, the Company corrected its prior statement regarding the number of patient deaths, and disclosed that four, not three, patients had died during the clinical trials of JCAR015. On this news, shares of Juno fell as much as 5% during intraday trading on July 14, 2016.

On October 19, 2016, the Court appointed Lead Plaintiff and Counsel.

A consolidated Complaint was filed on December 12, 2016.

On June 14, 2017, the Court denied Defendants' Motion to Dismiss.

On October 24, 2017, the Court granted Plaintiffs' Motion to Certify Class.

On June 28, 2018, the parties filed a proposed Order stipulating that they had agreed in principle to a Settlement of this action. On July 31, the parties entered into a Stipulation of Settlement. The Court issued an Order preliminarily approving the Settlement on August 8. On November 20, the Court granted final approval of the Settlement and entered Final Judgment. On September 11, 2019, the Court issued an Order for distribution of the Settlement fund.